Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Authors Della Pepa C, Banerjee S
Received 2 July 2014
Accepted for publication 2 July 2014
Published 20 August 2014 Volume 2014:7 Pages 1473—1474
Della Pepa C, Banerjee S. Onco Targets Ther. 2014;7:1025–1032.
On page 1027, please note that on Table 1, the population for the trial GOG170D (Burger et al34) with 62 patients was described as "≤2 lines of previous treatment, 58% Pl resistant, 26% Pl sensitive with Pl-free interval <12 months". However, the correct description of the population should be "≤2 lines of previous treatment, 58% Pl resistant, 42% Pl sensitive".
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]